BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38325600)

  • 1. Pathogenic Variant Intraductal Papillary Mucinous Neoplasms Tumors Show Increased Tumor Growth Compared With Those With Familial Pancreatic Cancer Kindreds: Prognostic Indicators.
    Cappell MS; Tobi M
    Clin Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38325600
    [No Abstract]   [Full Text] [Related]  

  • 2. Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.
    Murali K; Dwarte TM; Nikfarjam M; Tucker KM; Vaughan RB; Efthymiou M; Collins A; Spigelman AD; Salmon L; Johns AL; Williams DB; Delatycki MB; John T; Stoita A
    Hered Cancer Clin Pract; 2021 Aug; 19(1):33. PubMed ID: 34399810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraductal Papillary Mucinous Neoplasms in High-Risk Individuals: Incidence, Growth Rate, and Malignancy Risk.
    Overbeek KA; Koopmann BDM; Levink IJM; Tacelli M; Erler NS; Arcidiacono PG; Ausems MGE; Wagner A; van Eijck CH; Groot Koerkamp B; Busch OR; Besselink MG; van der Vlugt M; van Driel LMJW; Fockens P; Vleggaar FP; Poley JW; Capurso G; Cahen DL; Bruno MJ;
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):62-71.e7. PubMed ID: 37031711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.
    Tersmette AC; Petersen GM; Offerhaus GJ; Falatko FC; Brune KA; Goggins M; Rozenblum E; Wilentz RE; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Clin Cancer Res; 2001 Mar; 7(3):738-44. PubMed ID: 11297271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds.
    Porter N; Laheru D; Lau B; He J; Zheng L; Narang A; Roberts NJ; Canto MI; Lennon AM; Goggins MG; Hruban RH; Klein AP
    J Natl Cancer Inst; 2022 Dec; 114(12):1681-1688. PubMed ID: 36029239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.
    Kaiser J; Scheifele C; Hinz U; Leonhardt CS; Hank T; Koenig AK; Tjaden C; Hackert T; Bergmann F; Büchler MW; Strobel O
    Eur J Surg Oncol; 2022 Jun; 48(6):1309-1320. PubMed ID: 34920899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds.
    Klein AP; Brune KA; Petersen GM; Goggins M; Tersmette AC; Offerhaus GJ; Griffin C; Cameron JL; Yeo CJ; Kern S; Hruban RH
    Cancer Res; 2004 Apr; 64(7):2634-8. PubMed ID: 15059921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
    Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
    Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate Antigen 19-9 Is an Invasive Malignancy Preoperative Prognostic Factor for Intraductal Papillary Mucinous Neoplasms.
    Suzuki S; Shimoda M; Shimazaki J; Oshiro Y; Nishda K; Orimoto N; Nagakawa Y; Tsuchida A
    Eur Surg Res; 2021; 62(4):262-270. PubMed ID: 34344012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene.
    Hsu FC; Roberts NJ; Childs E; Porter N; Rabe KG; Borgida A; Ukaegbu C; Goggins MG; Hruban RH; Zogopoulos G; Syngal S; Gallinger S; Petersen GM; Klein AP
    JAMA Oncol; 2021 Nov; 7(11):1664-1668. PubMed ID: 34529012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN).
    Fujiyama Y; Kumamoto Y; Nishizawa N; Nakamoto S; Harada H; Yokota K; Tanaka Y; Igarashi K; Oiki H; Okuwaki K; Iwai T; Kajita S; Takahashi H; Tajima H; Kaizu T; Sasaki J; Watanabe M; Yamashita K
    Ann Surg Oncol; 2020 Oct; 27(10):4007-4016. PubMed ID: 32144623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
    Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
    Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition?
    Lubezky N; Ben-Haim M; Lahat G; Marmor S; Solar I; Brazowski E; Nackache R; Klausner JM
    Surgery; 2012 Jan; 151(1):70-5. PubMed ID: 21975290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of age of onset in pancreatic cancer kindreds.
    Brune KA; Lau B; Palmisano E; Canto M; Goggins MG; Hruban RH; Klein AP
    J Natl Cancer Inst; 2010 Jan; 102(2):119-26. PubMed ID: 20068195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare metastatic pancreatic tumors from lung cancer with cystic changes resembling intraductal papillary mucinous neoplasm: a case report.
    Watanabe A; Harimoto N; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Kubo N; Araki K; Suzuki A; Hara K; Shirabe K
    Surg Case Rep; 2020 May; 6(1):117. PubMed ID: 32468270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated pancreatic adenocarcinoma.
    Leonhardt CS; Hinz U; Kaiser J; Hank T; Tjaden C; Bergmann F; Hackert T; Büchler MW; Strobel O
    Eur J Surg Oncol; 2023 Jan; 49(1):113-121. PubMed ID: 35965217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
    Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
    PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis of pancreatic tumors.
    Yoshioka M; Uchinami H; Watanabe G; Sato T; Shibata S; Kume M; Ishiyama K; Takahashi S; Hashimoto M; Yamamoto Y
    Springerplus; 2015; 4():154. PubMed ID: 25883884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging morphological changes of intraductal papillary mucinous neoplasm of the pancreas was associated with its malignant transformation but not with development of pancreatic ductal adenocarcinoma.
    Kawada N; Uehara H; Nagata S; Tsuchishima M; Tsutsumi M; Tomita Y
    Pancreatology; 2015; 15(6):654-60. PubMed ID: 26433405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.